Below are some of the key findings from this GB syndrome therapeutics industry analysis report

The global Guillain-Barré syndrome therapeutics market is expected to grow at a CAGR of more than 5% during the forecast period

GB syndrome treatment industry growth is expected to accelerate over the next five years, driven by the recent approvals of immunoglobulins for the treatment of Guillain-Barré syndrome. Immunoglobulins are considered as the first line of treatment for Guillain-Barré syndrome and the market is forecasted to witness a rapid growth owing to the recent approvals of novel immunoglobulins from regulatory bodies. Guillain-Barré syndrome is regarded as a rare disorder, and the prevalence of the disease is much lower than other mainstream indicators such as diabetes and hypertension, which is compelling regulatory bodies to award special drug designations such as the orphan drug and fast track designations. Technavio’s GBS treatment industry analysis reveals promising markets around the world.

Get a FREE Sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

The Americas dominated the Guillain-Barré syndrome therapeutics market by region

The global GB syndrome treatment market was dominated by the Americas with over 40% of the global market share, followed by EMEA and APAC. In addition, the Americas will drive almost two-fifths of the growth for the global GBS treatment industry, while EMEA and APAC are also predicted to contribute significantly to the incremental growth in the forecast period. The global GB syndrome treatment market will witness APAC registering the fastest rate of growth during the forecast period, while EMEA will generate a higher CAGR than the Americas.

CSL, Grifols, and Kedrion are some of the key GB syndrome therapeutic companies

The global GB syndrome treatment market is forecasted to become reasonably fragmented with the emergence of many international and regional GBS treatment companies who offer therapeutics such as immunoglobulins and other therapeutics. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barré syndrome, which is expected to enhance the R&D activities of new drugs for the management of GB syndrome. Many established GB syndrome therapeutic companies are vying for their share of the global GBS treatment market, and the new players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several GB syndrome therapeutic companies, including:

• CSL
• Grifols
• Kedrion
• Octapharma
• Shire

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch